Galectin-8 Favors VEGF-Induced Angiogenesis: In Vitro Study in Human Umbilical Vein Endothelial Cells and In Vivo Study in Chick Chorioallantoic Membrane

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68378050%3A_____%2F20%3A00555715" target="_blank" >RIV/68378050:_____/20:00555715 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11120/20:43920188

Výsledek na webu

<a href="https://ar.iiarjournals.org/content/40/6/3191" target="_blank" >https://ar.iiarjournals.org/content/40/6/3191</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.21873/anticanres.14300" target="_blank" >10.21873/anticanres.14300</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Galectin-8 Favors VEGF-Induced Angiogenesis: In Vitro Study in Human Umbilical Vein Endothelial Cells and In Vivo Study in Chick Chorioallantoic Membrane

Popis výsledku v původním jazyce

Background/Aim: Although it has been accepted that the tandem repeat galectin-8 (Gal-8) is linked to angiogenesis, the underlying mechanisms in endothelial cells has remained poorly understood. In this study we aimed to investigate the effect of Gal-8 on selected biological processes linked to angiogenesis in in vitro and in vivo models. Materials and Methods: In detail, we assessed how exogenously added human recombinant Gal-8 (with or without vascular endothelial growth factor VEGF) affects selected steps involved in vessel formation in human umbilical vein endothelial cells (HUVECs) as well as using the chick chorioallantoic membrane (CAM) assay. Gene expression profiling of HUVECs was performed to extend the scope of our investigation. Results: Our findings demonstrate that Gal-8 in combination with VEGF enhanced cell proliferation and migration, two cellular events linked to angiogenesis. However, Gal-8 alone did not exhibit any significant effects on cell proliferation or on cell migration. The molecular analysis revealed that Gal-8 in the presence of VEGF influenced cytokine-cytokine receptor interactions, HIF-1 and PI3K/AKT signaling pathways. Gal-8 alone also targeted cytokine-cytokine receptor interactions, but with a different expression profile as well as a modulated focal adhesion and TNF signaling. Conclusion: Gal-8 promotes a pro-angiogenic phenotype possibly in a synergistic manner with VEGF.

Název v anglickém jazyce

Galectin-8 Favors VEGF-Induced Angiogenesis: In Vitro Study in Human Umbilical Vein Endothelial Cells and In Vivo Study in Chick Chorioallantoic Membrane

Popis výsledku anglicky

Background/Aim: Although it has been accepted that the tandem repeat galectin-8 (Gal-8) is linked to angiogenesis, the underlying mechanisms in endothelial cells has remained poorly understood. In this study we aimed to investigate the effect of Gal-8 on selected biological processes linked to angiogenesis in in vitro and in vivo models. Materials and Methods: In detail, we assessed how exogenously added human recombinant Gal-8 (with or without vascular endothelial growth factor VEGF) affects selected steps involved in vessel formation in human umbilical vein endothelial cells (HUVECs) as well as using the chick chorioallantoic membrane (CAM) assay. Gene expression profiling of HUVECs was performed to extend the scope of our investigation. Results: Our findings demonstrate that Gal-8 in combination with VEGF enhanced cell proliferation and migration, two cellular events linked to angiogenesis. However, Gal-8 alone did not exhibit any significant effects on cell proliferation or on cell migration. The molecular analysis revealed that Gal-8 in the presence of VEGF influenced cytokine-cytokine receptor interactions, HIF-1 and PI3K/AKT signaling pathways. Gal-8 alone also targeted cytokine-cytokine receptor interactions, but with a different expression profile as well as a modulated focal adhesion and TNF signaling. Conclusion: Gal-8 promotes a pro-angiogenic phenotype possibly in a synergistic manner with VEGF.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Anticancer Research

ISSN

0250-7005

e-ISSN

1791-7530

Svazek periodika

40

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

GR - Řecká republika

Počet stran výsledku

11

Strana od-do

3191-3201

Kód UT WoS článku

000538104800019

EID výsledku v databázi Scopus

—